HETEROPARK-Síntesis y validación de fármacos antiparkinsonianos destinados a los heterómeros de GPCR

  • Investigador principal: José Luis Lanciego Pérez

  • Organismo de financiación: ERANET Neuron - MICINN

  • Dotación financiera: 160.000 €

This consortium will carry out complementary translational research to propose a new therapeutic approach to Parkinson's disease with the possibility of beginning clinical trials in 3 to 5 years. The approach consists of a combination of innovative compounds that alleviate the symptoms of Parkinson's and minimize the side effects caused by current therapies. The focus includes the design of new compounds and new therapeutic approaches based on combinations of drugs and dual drugs to act on the heteromers of the G-protein coupled receptors.

The coordinator of the consortium has discovered trimers made up of D2 dopamine receptors, CB1 cannabinoid receptors, and A2A adenosine receptors in the corpus striatum, the target organ of the Parkinson's therapies, and has the necessary knowledge to detect abnormal trimers in Parkinson's. One member of the consortium has the necessary knowledge and skill to synthesize new patentable compounds for these receptors and even dual compounds that act simultaneously on two different receptors. The other two members of the consortium have pertinent knowledge of the development of Parkinson's models in animals, one in rats and the other in primates, and on the validation of new therapeutic approaches to Parkinson's.

What is required to begin phase-I clinical trials in humans is the validation of new therapies that act on the striatal receptors, first in rodents and then in primates.

Istituto Nazionale dei Tumori: Fondazione IRCCS; Rheinische Friedrich-Wilhelms-Universität Bonn; Universitat de Barcelona